skip to main content, skip to Quick links, or skip to Search

main content


Double-Blinded Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Grade II and III Non-Resectable Mast Cell Tumors in Dogs


Mast cell tumors (MCT) in dogs are very common, accounting for approximately 20% of all skin tumors in dogs. They can arise from any skin site on the body, and while they often appear small and somewhat insignificant, they can be a very serious form of cancer in the dog. Some MCT’s are easily removed without development of further problems; however, others may lead to a life-threatening disease if not properly identified and treated.

The purpose of this study is to evaluate the efficacy and safety of masitinib in comparison to placebo in dogs with grade 2-3 non-resectable mast cell tumors, not previously treated by chemotherapy (other than corticosteroids) or radiotherapy. Masitinib is a tyrosine kinase inhibitor (TKI) that has been shown to improve long-term survival of dogs with non-resectable tumors.


Financial Incentive:


Clinical Studies Core
Phone: 919-515-2633 or 919-513-6384; Fax: 919-513-6680


Page last updated August 08, 2014